Management of COPD Exacerbation

Initial Assessment

• The British Thoracic Society recommends obtaining arterial blood gas analysis, chest radiograph, full blood count, urea and electrolytes, and ECG in patients with COPD exacerbation 1, 2
• The British Thoracic Society suggests recording initial FEV1 and/or peak flow when possible in patients with COPD exacerbation 1
• The British Thoracic Society recommends sending sputum for culture if purulent and considering blood cultures if pneumonia is suspected in patients with COPD exacerbation 1

Oxygen Therapy

• The American Thoracic Society recommends targeting oxygen saturation of 88-92% to improve hypoxemia without causing carbon dioxide retention in patients with COPD exacerbation 3
• The British Thoracic Society suggests initially using controlled oxygen therapy with FiO2 ≤28% via Venturi mask or ≤2 L/min via nasal cannulae until arterial blood gases are known in patients with known COPD aged 50 years or more 1, 2
• The British Thoracic Society recommends checking blood gases within 60 minutes of starting oxygen and within 60 minutes of any change in inspired oxygen concentration in patients with COPD exacerbation 1

Bronchodilator Therapy

• The British Thoracic Society recommends administering nebulized bronchodilators immediately on arrival and at 4-6 hourly intervals thereafter in patients with COPD exacerbation 1, 4
• The British Thoracic Society suggests using either a beta-agonist or an anticholinergic for moderate exacerbations and both for severe exacerbations in patients with COPD exacerbation 1, 4

Corticosteroid Therapy

• The British Thoracic Society recommends using oral prednisolone 30-40 mg daily for 5-7 days in patients with COPD exacerbation 4
• The British Thoracic Society suggests discontinuing corticosteroids after the acute episode (usually 7-14 days) unless specifically indicated for long-term treatment in patients with COPD exacerbation 4

Antibiotic Therapy

• The American Thoracic Society recommends providing antibiotics when patients present with at least two of the following: increased dyspnea, increased sputum volume, and purulent sputum in patients with COPD exacerbation 3
• The American Thoracic Society suggests that antibiotics reduce the risk of short-term mortality by 77%, treatment failure by 53%, and sputum purulence by 44% in patients with COPD exacerbation 3
• The British Thoracic Society recommends first-line options such as amoxicillin or tetracycline and second-line options such as broad-spectrum cephalosporins or newer macrolides for patients with COPD exacerbation 1

Ventilatory Support

• The American Thoracic Society recommends considering non-invasive ventilation (NIV) as the first mode of ventilation for patients with acute respiratory failure 3
• The American Thoracic Society suggests that NIV reduces mortality and intubation rates by 80-85% in patients with COPD exacerbation 3
• The European Respiratory Society recommends considering invasive mechanical ventilation if NIV fails in patients with COPD exacerbation 5

Additional Measures

• The British Thoracic Society recommends considering diuretics if peripheral edema and raised jugular venous pressure are present in patients with COPD exacerbation 4
• The British Thoracic Society suggests considering intravenous methylxanthines if response to nebulized bronchodilators is poor in patients with COPD exacerbation 4
• The British Thoracic Society recommends prophylactic subcutaneous heparin for patients with acute-on-chronic respiratory failure 4

Discharge Planning and Follow-up

• The American Thoracic Society recommends arranging early follow-up (<30 days) after discharge to review discharge therapy and make necessary changes in patients with COPD exacerbation 3
• The American Thoracic Society suggests additional follow-up at 3 months to ensure return to stable state in patients with COPD exacerbation 3

Management of COPD Exacerbations

Initial Assessment

• The European Respiratory Society and American Thoracic Society recommend that COPD exacerbations be assessed for severity, identification of the cause, and determination of appropriate treatment setting 6
• COPD exacerbations present as worsening of previous stable situation with increased dyspnea, sputum volume, sputum purulence, wheeze, and chest tightness 7
• Differential diagnoses to consider include pneumonia, pneumothorax, left ventricular failure/pulmonary edema, pulmonary embolism, lung cancer, and upper airway obstruction 7

Bronchodilator Therapy

• The American Thoracic Society recommends short-acting bronchodilators as the first-line treatment for COPD exacerbations 8
• Add or increase beta-agonists and/or anticholinergic drugs to improve airflow obstruction 7
• For severe exacerbations, consider combination therapy with both beta-agonists and anticholinergics 6

Corticosteroid Therapy

• The European Respiratory Society recommends systemic corticosteroids to improve lung function, oxygenation, and shorten recovery time and hospitalization duration 8
• Oral corticosteroids (typically 30-40 mg prednisolone daily for 5-7 days) are recommended for most patients with COPD exacerbations 9, 7
• Corticosteroids should not be routinely continued long-term after an exacerbation 7

Antibiotic Therapy

• The American Thoracic Society recommends antibiotics when patients present with at least two of the following: increased breathlessness, increased sputum volume, and development of purulent sputum 8, 7
• Antibiotics shorten recovery time and reduce the risk of early relapse, treatment failure, and hospitalization duration 8
• Choice of antibiotic should consider local resistance patterns and patient risk factors 9

Oxygen Therapy

• The goal of oxygen therapy is to achieve a PaO2 of at least 6.6 kPa (50 mmHg) without causing respiratory acidosis 10
• Controlled oxygen therapy is crucial in patients with COPD to prevent worsening hypercapnia 6

Ventilatory Support

• The American Thoracic Society recommends noninvasive ventilation (NIV) as the first mode of ventilation for patients with acute or acute-on-chronic respiratory failure 8
• NIV reduces mortality and need for intubation in patients with acute hypercapnic respiratory failure 9
• Consider NIV when patients have persistent hypoxemia despite supplemental oxygen, respiratory acidosis (pH < 7.35), or severe dyspnea with signs of respiratory muscle fatigue 6

Hospitalization Decision

• Factors favoring hospitalization include severe symptoms, acute respiratory failure, new physical signs, failure to respond to initial treatment, significant comorbidities, and insufficient home support 8, 10

Follow-up Care

• Arrange follow-up after an acute exacerbation to assess response to treatment 7
• Consider early pulmonary rehabilitation (within 3 weeks after hospital discharge) to improve outcomes 9
• Review smoking status, inhaler technique, and maintenance medications 7
• Develop strategies to prevent future exacerbations 8

Common Pitfalls and Caveats

• Avoid prolonged courses of systemic corticosteroids beyond 5-7 days due to increased risk of adverse effects 9
• Methylxanthines (theophylline) are not recommended due to limited efficacy and potential side effects 8